Terumo

What Terumo does

Terumo Corporation is a Tokyo-headquartered global medical technology company founded in 1921 and listed on the Prime Market of the Tokyo Stock Exchange (Code: 4543). It develops, manufactures, and sells medical devices across three operating companies and nine business divisions: the Cardiac and Vascular Company (Terumo Interventional Systems, Terumo Neuro, Terumo Cardiovascular, Terumo Aortic); the Medical Care Solutions Company (Hospital Care Solutions, Life Care Solutions, Pharmaceutical Solutions); Terumo Blood and Cell Technologies; and Terumo Organ Technologies. Its product portfolio spans drug-eluting coronary stents (Ultimaster), multimodal intravascular imaging (OPUSWAVE combining OFDI and IVUS), neurovascular embolization and stroke devices, ECMO systems, blood collection and apheresis equipment, cell therapy manufacturing platforms (Quantum Flex), peritoneal dialysis systems, insulin delivery products, prefilled syringe/CDMO services, and ex vivo organ perfusion devices (OrganOx). Terumo serves hospitals, blood centers, pharmaceutical companies, cell and gene therapy developers, transplant centers, and chronic disease patients across more than 160 countries, with 31,185 consolidated employees and approximately 8,500 patents globally.

Revenue is generated primarily through direct sales of hardware devices and consumables to enterprise hospital and blood center customers via regional subsidiaries and dedicated specialty sales forces, supplemented by CDMO services for pharmaceutical companies. Recent reported revenue reached JPY 1,131.9 billion for FYE March 2026, with record operating profit of JPY 144.9 billion at the Q3 FY2025 mark, supported by 9% growth in North America and approximately 7.2% of revenue reinvested in R&D. The company also runs a global training infrastructure (Terumo Medical Pranex, Elevate IR, Center of Excellence partnerships) that functions as a clinical-adoption lever alongside device sales.

Name

Terumo

Legal name

Terumo Corporation

Website

https://terumo.com

Company type

Public

Founded year

1921

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Terumo Corporation is a 104-year-old Japanese global medical device company that designs, manufactures, and sells therapeutic, diagnostic, and cell therapy products across vascular intervention, cardiac surgery, blood management, hospital care, diabetes care, and pharmaceutical CDMO services to healthcare providers in 160+ countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical and Medicine Manufacturing (3254), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Pharmaceutical & Medical Plastic Packaging Manufacturing (IMANAEAK)

Keywords

• Medical devices manufacturing
• Vascular intervention systems
• Cardiovascular surgery devices
• Blood management technologies
• Cell therapy manufacturing

Headquarters

HQ city

Somerset

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Terumo generates revenue through the sale of medical devices and equipment including vascular intervention products, cardiac surgery devices, blood transfusion systems, and hospital care products. Revenue reported as JPY 1,131.9 billion for FYE March 2026.
2. Pharmaceutical Solutions (CDMO): Contract Development and Manufacturing Organization services for pharmaceutical companies, providing prefilled syringes, drug-device combination products, and manufacturing services from clinical trials to commercialization.
3. Blood and Cell Technologies: Sale of blood collection, processing, and cell therapy equipment along with consumables including blood bags, apheresis systems, and pathogen reduction technology.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Terumo develops, manufactures, and sells medical devices and pharmaceuticals across three core companies: Cardiac and Vascular (vascular intervention stents, neurovascular coils, cardiac surgery and ECMO systems, aortic grafts), Medical Care Solutions (infusion/syringe pumps, safety syringes, peritoneal dialysis, insulin delivery, CDMO services), and Blood and Cell Technologies (blood collection and apheresis systems, pathogen reduction, Quantum Flex cell expansion). The company supplies hospitals, blood centers, pharmaceutical manufacturers, and transplant centers in 160+ countries. Revenue is generated through direct sales of devices and consumables plus contract development and manufacturing services.

Product overview

Terumo is a global medical technology company offering over 50,000 products across 3 companies and 9 business divisions. The company operates through: Cardiac and Vascular Company (Terumo Interventional Systems, Terumo Neuro, Terumo Cardiovascular, Terumo Aortic) providing vascular intervention and cardiac surgery devices including Ultimaster drug-eluting stents, OPUSWAVE imaging systems, and neurovascular coils; Medical Care Solutions Company (Hospital Care Solutions, Life Care Solutions, Pharmaceutical Solutions) covering diabetes care, peritoneal dialysis, infusion systems, and CDMO services; Blood and Cell Technologies Company providing blood collection, apheresis, and cell therapy manufacturing solutions including the Quantum Flex platform; and Terumo Organ Technologies offering organ preservation devices like the OrganOx liver preservation system. The portfolio spans from disposable medical devices to advanced therapeutic systems and automated manufacturing platforms.

Differentiator

Problem solved

Functional benefit

Brands

• Ultimaster: Drug-eluting coronary stent system
• OPUSWAVE
• SurTract
• WEB Embolization System
• Medisafe
• Terumo Ventures
• C> Ecosystem Blueprint

Products and services

• Terumo Interventional Systems (TIS) Vascular intervention products for treating blood vessel diseases of the heart and lower limbs, including imaging systems, introducer sheaths, guidewires, angiographic catheters, drug-eluting stents, balloon catheters, peripheral stents, and embolization coils for hospitals and healthcare systems.
• Terumo Neuro Neuroendovascular technologies for treating ischemic stroke and brain aneurysms through catheter-based minimally invasive procedures, including hydrogel embolic coils, intrasaccular devices, flow diverters, aspiration catheters, clot retrieval devices, and micro catheters.
• Terumo Cardiovascular Medical devices for cardiac surgery including cardiopulmonary bypass systems, oxygenators, ECMO systems for emergency care, and off-pump coronary artery bypass surgery products.
• Terumo Aortic Vascular graft business providing surgical grafts, stent grafts, and hybrid devices for treating thoracic and abdominal aortic aneurysms and dissection.
• Hospital Care Solutions Solutions for medical safety, infection prevention, and cost efficiency including perioperative products, advanced drug management systems with infusion and syringe pumps, outpatient chemotherapy devices, and renal care products for peritoneal dialysis.
• Life Care Solutions Chronic disease management solutions including diabetes care products (blood glucose monitors, insulin needles, insulin patch pumps), bedside care devices, and disease progression prevention monitoring systems.
• Pharmaceutical Solutions CDMO services combining prefilled drug product technology with drug delivery devices, supporting pharmaceutical companies from clinical trial manufacturing to full commercialization.
• Terumo Blood and Cell Technologies Blood and cell collection, processing, and therapy solutions including automated blood collection systems, pathogen reduction technology, plasma donation systems, centrifugal apheresis systems, and cell expansion systems for cell and gene therapy.
• Terumo Organ Technologies Organ preservation and transplantation solutions including the OrganOx liver preservation device, expanding transplant opportunities globally.
• Ultimaster Drug-Eluting Stent Drug-eluting stent (DES) for coronary artery disease treatment, providing controlled drug release to prevent restenosis.
• OPUSWAVE Dual Sensor Imaging System Multimodal intravascular imaging system combining Optical Frequency Domain Imaging (OFDI) and Intravascular Ultrasound (IVUS) technologies into a single device for coronary artery disease treatment.
• DualView Imaging Catheter FDA-cleared imaging catheter for intravascular imaging, used as part of the OPUSWAVE multimodal imaging system.
• SurTract Safety Syringe Safety syringe with automatic needle retraction powered by SafeR passive safety technology from Roncadelle Operations, designed to reduce needle-stick injuries in hospitals, clinics, and emergency-care settings.
• R2P NaviCross Peripheral Support Catheter Peripheral support catheter with double-braided stainless-steel construction for superior trackability and torque control in radial-to-peripheral procedures; available in 200 cm length.
• OrganOx Liver Preservation Device Device for preserving donor livers during transport to medical settings for transplantation, acquired through OrganOx Limited acquisition.
• Quantum Flex Cell Expansion System Automated cell expansion platform for scalable cell therapy manufacturing, enabling automated cell activation, transduction, and expansion within a closed bioreactor system.
• Insulin Patch Pump Japan's first insulin patch pump enabling tube-free insulin delivery with less restrictions on daily activities for diabetes patients.

Quantifiable outcome

• Record revenue of JPY 831.6 billion in Q3 FY2025, with 9% growth in North America
• +3 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered strategic and core.

• AIG HospitalsstrategicStrategic or Co-development Partner · 22 April 2026MoU to establish Centre of Excellence for Interventional Radiology in India under Terumo's 'Elevate IR' programme. AIG Hospitals serves as first training centre offering simulation-based training, expert-led sessions, and case-based discussions supported by Terumo India Skill Lab.
• Tata ElxsistrategicTechnology or Integration · 18 March 2026Launch of global offshore development center for Terumo's medical device engineering. The Terumo-Tata Elxsi Offshore Development Center brings together design, software, engineering, and regulatory teams, incorporating AI and digital engineering tools to accelerate product development.
• Taiwan Bio TherapeuticscoreStrategic or Co-development Partner · 17 March 2026Partnership to transition regulatory T-cell manufacturing onto Terumo's automated Quantum Flex platform. Taiwan Bio's TregCel therapy TRK-001 (Phase 2 for kidney transplant rejection) will be adapted to the integrated 3-in-1 workflow automating cell activation, transduction, and expansion.
• CiRA FoundationcoreStrategic or Co-development Partner · 5 March 2026Joint research selected for AMED (Japan Agency for Medical Research and Development) funding to develop automated and standardized workflows for iPS cell manufacturing. Collaboration uses Terumo's Quantum Flex Cell Expansion System and will test new protocols at CiRA Foundation's FiT facility.
• APAC Regional Cell and Gene Therapy DeveloperscoreStrategic or Co-development Partner · 5 March 2026Launch of C> Ecosystem Blueprint collaborative model to support cell and gene therapy development in Asia-Pacific. Multiple collaborations underway with regional partners and developers to address fragmented workflows, high costs, and skill shortages.
• Roncadelle Operations S.r.l.coreOEM/ Whitelabel/ Licensing Partner · 6 January 2026Licensing partnership for SafeR passive safety technology powering Terumo's SurTract Safety Syringe launch in the US market. Distribution begins Q1 2026 across hospitals, clinics, and emergency-care settings.
• GeisingerstrategicStrategic or Co-development Partner · 29 October 2025Collaboration for stroke education and neurovascular innovation in recognition of World Stroke Day 2025. Partnership released educational video and awareness campaign focused on early stroke recognition and minimally invasive treatment advancements.
• Orchestra BioMedcoreStrategic or Co-development Partner · 28 October 2025Strategic partnership involving $30 million payment from Terumo including right of first refusal for Virtue SAB (sirolimus-coated balloon) for coronary artery disease treatments. Terumo also invested $20 million in Orchestra BioMed through preferred stock. The partnership supports development of Virtue SAB and other cardiovascular therapies.
• OrganOx LimitedcoreStrategic or Co-development Partner · 25 August 2025Terumo acquired remaining 99.5% stake in OrganOx for $1.5 billion, making it a wholly owned subsidiary. OrganOx specializes in ex vivo organ perfusion technology for liver transplantation, with plans to expand beyond liver transplantation.
• Pharmaceutical Companies (CDMO Partners)coreChannel Partner/ Reseller/ DistributorPharmaceutical Solutions division serves as CDMO partner providing integrated parenteral drug development from formulation and sterile fill-finish to device assembly, labeling, and final packaging. Noritsugu Fujita, President of Pharmaceutical Solutions Division, leads the integrated CDMO model.

Scale indicators12 records

Direct peers

• Medtronic: Global medical device leader with deep overlap in cardiac and vascular intervention, including drug-eluting stents, cardiac surgery, and neurovascular devices that directly compete with Terumo's Cardiac and Vascular Company portfolio.
• Abbott: Major competitor in interventional cardiology (XIENCE stents), structural heart, neurovascular, and diabetes care, with comparable global commercial reach and a similarly diversified device portfolio across cardiac, vascular, and chronic care.
• Boston Scientific: Direct competitor in interventional cardiology, peripheral intervention, and neurovascular, with overlapping drug-eluting stent, imaging, and embolization product lines that compete head-to-head with Terumo Interventional Systems and Terumo Neuro.
• Edwards Lifesciences: Specialist peer in cardiac surgery and structural heart, with overlapping heart valve, surgical, and critical care product portfolios that compete directly with Terumo Cardiovascular's cardiopulmonary bypass, oxygenator, and ECMO systems.
• B. Braun: Closely comparable peer in infusion therapy, prefilled syringes, dialysis (peritoneal), and surgical devices, with overlapping Hospital Care Solutions and Life Care Solutions product portfolios across global markets.
• West Pharmaceutical Services: Direct competitor in elastomeric components, prefilled syringe systems, and drug-device combination products, serving the same pharmaceutical customer base as Terumo's Pharmaceutical Solutions CDMO division.
• Teleflex: Specialist medical device peer with overlapping vascular access, interventional, and surgical portfolios that compete with Terumo's interventional systems and hospital care product lines.
• Haemonetics: Specialist peer in blood and plasma component collection, processing, and apheresis systems that compete directly with Terumo Blood and Cell Technologies' portfolio of automated blood collection and processing platforms.

Broad incumbents

• Becton, Dickinson and Company (BD): Large diversified medical device incumbent with overlapping drug delivery, prefilled syringe, injection, and infusion portfolios, plus blood collection products that compete with Terumo's Hospital Care Solutions and Blood and Cell Technologies businesses.
• Fresenius Kabi: Broad incumbent in infusion therapy, injection devices, clinical nutrition, and dialysis products, with overlap to Terumo's Hospital Care Solutions and Life Care Solutions businesses across global markets.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLJBTjyIY2iAc-dxdBWkW6-IdRjLVjkzLI
• LinkedInlinkedin.com/company/terumo-global

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries19 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terumo